Umeclidinium bromide/vilanterol

{{Short description|Pharmaceutical medication}}

{{Use dmy dates|date=March 2024}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Infobox drug

| type = combo

| image = Umeclidinium bromide and vilanterol.svg

| width = 250

| caption = Umeclidinium bromide (TOP), vilanterol (BOTTOM)

| component1 = Umeclidinium bromide

| class1 = Muscarinic antagonist

| component2 = Vilanterol

| class2 = Ultra-long-acting β₂ agonist

| tradename = Anoro Ellipta, others

| Drugs.com = {{Drugs.com|ppa|umeclidinium-and-vilanterol}}

| MedlinePlus =

| DailyMedID = Anoro

| pregnancy_AU = B3

| pregnancy_category=

| routes_of_administration = Inhalation

| ATC_prefix = R03

| ATC_suffix = AL03

| legal_AU = S4

| legal_AU_comment = {{cite web | title=Prescription medicines: registration of new chemical entities in Australia, 2014 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/resources/resource/guidance/prescription-medicines-registration-new-chemical-entities-australia-2014 | access-date=10 April 2023}}

| legal_CA =

| legal_UK = POM

| legal_UK_comment = {{cite web | title=Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC) | website=(emc) | date=7 October 2019 | url=https://www.medicines.org.uk/emc/product/5423 | access-date=29 October 2020}}

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Anoro Ellipta- umeclidinium bromide and vilanterol trifenatate powder | website=DailyMed | date=2 June 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dbd0671-c565-40c5-bf0f-e324db26799c | access-date=24 November 2024}}

| legal_EU = Rx-only

| legal_EU_comment =

| legal_status =

| CAS_number = 2446159-58-4

| PubChem =

| DrugBank =

| KEGG = D10533

}}

Umeclidinium bromide/vilanterol, sold under the brand name Anoro Ellipta, among others, is a fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD).{{cite journal | vauthors = Feldman GJ, Edin A | title = The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects | journal = Therapeutic Advances in Respiratory Disease | volume = 7 | issue = 6 | pages = 311–9 | date = December 2013 | pmid = 24004659 | doi = 10.1177/1753465813499789 | s2cid = 5744282 }}{{Cite news | title = FDA Approves Umeclidinium and Vilanterol Combo for COPD | url = http://www.medscape.com/viewarticle/817964 | date = 18 December 2013 | publisher = Medscape}} It is administered by inhalation.

The most common side effects include upper respiratory tract infections, urinary tract infections, pharyngitis, sinusitis, nasopharyngitis, headache, cough, oropharyngeal pain, constipation and dry mouth.{{cite web | title=Anoro Ellipta EPAR | website=European Medicines Agency (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/anoro-ellipta | access-date=28 October 2020}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

In 2022, it was the 211th most commonly prescribed medication in the United States, with more than 1{{nbsp}}million prescriptions.{{cite web | title=The Top 300 of 2022 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=30 August 2024 | archive-date=30 August 2024 | archive-url=https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}{{cite web | title = Umeclidinium; Vilanterol Drug Usage Statistics, United States, 2013 - 2022 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/UmeclidiniumVilanterol | access-date = 30 August 2024 }}